Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19
El nuevo coronavirus es el causante de la actual pandemia que se caracteriza por el cuadro de un síndrome respiratorio agudo. Históricamente ya existieron epidemias dadas por virus pertenecientes a la misma familia de coronavirus, como lo son el SARS-CoV y MERS-CoV causantes del síndrome respiratori...
- Autores:
-
Navarro Gamarra, Marco André
Mogollon Oñoro, Cesar Alexandro
Pastrana Donado, Steven Alberto
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- spa
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/7978
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/7978
- Palabra clave:
- Coronavirus
COVID-19
SARS-CoV-2
Hidroxicloroquina
Remdesivir
ACE-2
Coronavirus
COVID-19
SARS-CoV-2
Hydroxychloroquine
Remdesivir
ACE-2
- Rights
- restrictedAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
| id |
USIMONBOL2_e5d34d5278404abfbfbe9919e17433da |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/7978 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| title |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| spellingShingle |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 Coronavirus COVID-19 SARS-CoV-2 Hidroxicloroquina Remdesivir ACE-2 Coronavirus COVID-19 SARS-CoV-2 Hydroxychloroquine Remdesivir ACE-2 |
| title_short |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| title_full |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| title_fullStr |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| title_full_unstemmed |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| title_sort |
Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19 |
| dc.creator.fl_str_mv |
Navarro Gamarra, Marco André Mogollon Oñoro, Cesar Alexandro Pastrana Donado, Steven Alberto |
| dc.contributor.advisor.none.fl_str_mv |
Trindade, Cristiano |
| dc.contributor.author.none.fl_str_mv |
Navarro Gamarra, Marco André Mogollon Oñoro, Cesar Alexandro Pastrana Donado, Steven Alberto |
| dc.subject.spa.fl_str_mv |
Coronavirus COVID-19 SARS-CoV-2 Hidroxicloroquina Remdesivir ACE-2 |
| topic |
Coronavirus COVID-19 SARS-CoV-2 Hidroxicloroquina Remdesivir ACE-2 Coronavirus COVID-19 SARS-CoV-2 Hydroxychloroquine Remdesivir ACE-2 |
| dc.subject.eng.fl_str_mv |
Coronavirus COVID-19 SARS-CoV-2 Hydroxychloroquine Remdesivir ACE-2 |
| description |
El nuevo coronavirus es el causante de la actual pandemia que se caracteriza por el cuadro de un síndrome respiratorio agudo. Históricamente ya existieron epidemias dadas por virus pertenecientes a la misma familia de coronavirus, como lo son el SARS-CoV y MERS-CoV causantes del síndrome respiratorio agudo severo y el síndrome respiratorio del medio oriente respectivamente. La estandarización de los datos epidemiológicos en la actualidad es un proceso de difícil unificación ya que las cifras de infectados y muertos varía cada día, esto por el curso actual de la pandemia. Las manifestaciones clínicas de los individuos infectados por SARS-CoV2 pueden ir desde muy leves hasta presentar cuadros graves que incluso pueden llegar a acabar con la vida de estos, sin embargo existe un porcentaje de pacientes que cursan con la enfermedad de manera asintomática. La manera más adecuada de establecer un diagnóstico acertado se basa en la detección del agente patógeno apoyado en los criterios de Koch. Actualmente hay una gran variedad de posibles terapias, de las cuales aún no existen los suficientes datos para avalar alguna de ellas, sin embargo nos encontramos en un periodo de prueba, se siguen realizando diversos estudios dirigidos hacia aquellos fármacos y regímenes de tratamiento más prometedores, hasta ahora con resultados poco alentadores, y a la espera de una vacuna muy necesaria en estos casos, para el control de la pandemia a medio y largo plazo. |
| publishDate |
2020 |
| dc.date.issued.none.fl_str_mv |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2021-07-12T19:29:47Z |
| dc.date.available.none.fl_str_mv |
2021-07-12T19:29:47Z |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.driver.eng.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| dc.type.spa.spa.fl_str_mv |
Trabajo de grado - pregrado |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/7978 |
| url |
https://hdl.handle.net/20.500.12442/7978 |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.rights.none.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_16ec |
| dc.rights.uri.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.eng.fl_str_mv |
info:eu-repo/semantics/restrictedAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_16ec |
| eu_rights_str_mv |
restrictedAccess |
| dc.format.mimetype.spa.fl_str_mv |
pdf |
| dc.publisher.spa.fl_str_mv |
Ediciones Universidad Simón Bolívar Facultad de Ciencias de la Salud |
| institution |
Universidad Simón Bolívar |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/57522ac1-5323-4cb5-824a-16463a8011bb/download https://bonga.unisimon.edu.co/bitstreams/5db4a1f4-4f0c-4217-874d-b848329c994c/download https://bonga.unisimon.edu.co/bitstreams/ef9e3b3c-711c-4c6e-a1e0-27717d82c21c/download https://bonga.unisimon.edu.co/bitstreams/66ab097c-d307-4843-8d56-3f543f212fdf/download https://bonga.unisimon.edu.co/bitstreams/6a7e6f4d-3dfb-451c-bda4-95fdd7f4b023/download https://bonga.unisimon.edu.co/bitstreams/8d1e0fe5-094e-4653-9835-05f3d2187bb7/download https://bonga.unisimon.edu.co/bitstreams/f4e05a1c-8f4c-4ba1-bad2-35ca3bd3bb51/download https://bonga.unisimon.edu.co/bitstreams/f1792514-94d4-4a0c-b3dd-c417dddc8d7a/download https://bonga.unisimon.edu.co/bitstreams/048a5952-09f7-49d3-9501-14b9111b8860/download https://bonga.unisimon.edu.co/bitstreams/3a6b1244-2857-467c-829f-5d03a6b96ea8/download https://bonga.unisimon.edu.co/bitstreams/dd62304e-70e0-4aba-9079-c007456f9415/download https://bonga.unisimon.edu.co/bitstreams/e38d9a50-8745-4e02-95cb-90826445db9b/download https://bonga.unisimon.edu.co/bitstreams/7f3bbce7-b8c5-4fd3-bfca-1781a8d16868/download https://bonga.unisimon.edu.co/bitstreams/7b056d31-e096-45ff-aaea-7b9b184726c0/download https://bonga.unisimon.edu.co/bitstreams/1b9463ac-fa94-4608-9434-7d17bbdad913/download https://bonga.unisimon.edu.co/bitstreams/1a06d243-cacd-4001-9f20-cfc37de5fa87/download |
| bitstream.checksum.fl_str_mv |
cf2d00e07eea1ca2ca2ae94f464143a2 2e02d18653c971dbd183b292bc06affc 4460e5956bc1d1639be9ae6146a50347 2a1661e5960a7bab4fd8dda692fb677c 147b8aa26921e4e342fbcad1633f2f29 82baf24a4e2edc7c5993fc6486bc718d 02e638b876d4862ac7436548eda23760 a12b79e069ffd7e6808a4f0422845969 02e638b876d4862ac7436548eda23760 a12b79e069ffd7e6808a4f0422845969 3c4cd5e38e5143ac2cd1967f60a33976 4d878871ab6bee20fb82b13935760938 19ff5bdadc5d96e0328dd6c8ff9cbacd 855a0958350f2d2c52cc9fd0e20e1394 19ff5bdadc5d96e0328dd6c8ff9cbacd 855a0958350f2d2c52cc9fd0e20e1394 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
| repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
| _version_ |
1814076150885908480 |
| spelling |
Trindade, CristianoNavarro Gamarra, Marco André24bee7de-7288-4188-8d46-b0f7a2cb855eMogollon Oñoro, Cesar Alexandroa6c0935c-c3c1-426d-b399-17464065a61aPastrana Donado, Steven Albertoefa5a455-176e-40f4-b922-935aa0e997132021-07-12T19:29:47Z2021-07-12T19:29:47Z2020https://hdl.handle.net/20.500.12442/7978El nuevo coronavirus es el causante de la actual pandemia que se caracteriza por el cuadro de un síndrome respiratorio agudo. Históricamente ya existieron epidemias dadas por virus pertenecientes a la misma familia de coronavirus, como lo son el SARS-CoV y MERS-CoV causantes del síndrome respiratorio agudo severo y el síndrome respiratorio del medio oriente respectivamente. La estandarización de los datos epidemiológicos en la actualidad es un proceso de difícil unificación ya que las cifras de infectados y muertos varía cada día, esto por el curso actual de la pandemia. Las manifestaciones clínicas de los individuos infectados por SARS-CoV2 pueden ir desde muy leves hasta presentar cuadros graves que incluso pueden llegar a acabar con la vida de estos, sin embargo existe un porcentaje de pacientes que cursan con la enfermedad de manera asintomática. La manera más adecuada de establecer un diagnóstico acertado se basa en la detección del agente patógeno apoyado en los criterios de Koch. Actualmente hay una gran variedad de posibles terapias, de las cuales aún no existen los suficientes datos para avalar alguna de ellas, sin embargo nos encontramos en un periodo de prueba, se siguen realizando diversos estudios dirigidos hacia aquellos fármacos y regímenes de tratamiento más prometedores, hasta ahora con resultados poco alentadores, y a la espera de una vacuna muy necesaria en estos casos, para el control de la pandemia a medio y largo plazo.The new coronavirus is the cause of the current pandemic that is characterized by the picture of an acute respiratory syndrome. Historically, there have already been epidemics due to viruses belonging to the same coronavirus family, such as SARS-CoV and MERS-CoV, which cause severe acute respiratory syndrome and Middle Eastern respiratory syndrome, respectively. The standardization of epidemiological data at present is a difficult process to unify since the numbers of infected and dead vary every day, this due to the current course of the pandemic. The clinical manifestations of individuals infected with SARS-CoV2 can range from very mild to presenting severe symptoms that can even end their lives, however there is a percentage of patients who present with the disease asymptomatically. The most appropriate way to establish a correct diagnosis is based on the detection of the pathogen supported by Koch's criteria. Currently there are a wide variety of possible therapies, of which there are not yet enough data to support any of them, however we are in a trial period, various studies are still being conducted aimed at those drugs and most promising treatment regimens, so far with little encouraging results, and waiting for a much-needed vaccine in these cases, to control the pandemic in the medium and long term.pdfspaEdiciones Universidad Simón BolívarFacultad de Ciencias de la SaludAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/restrictedAccesshttp://purl.org/coar/access_right/c_16ecCoronavirusCOVID-19SARS-CoV-2HidroxicloroquinaRemdesivirACE-2CoronavirusCOVID-19SARS-CoV-2HydroxychloroquineRemdesivirACE-2Covid-19: Revisión de literatura de los posibles tratamientos contra el COVID-19info:eu-repo/semantics/bachelorThesisTrabajo de grado - pregradohttp://purl.org/coar/resource_type/c_7a1fMalik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40(1):68‐76. DOI:10.1080/01652176.2020.1727993Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395 (10223): 497-506. DOI:https://doi.org/10.1016/S0140-6736(20)30183-5Kamel Boulos, M.N., Geraghty, E.M. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int J Health Geogr 19, 8 (2020). DOI:https://doi.org/10.1186/s12942-020-00202-8.The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly, 2020, 2(8): 113-122.Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z et al. Characteristics of COVID-19 infection in Beijing JOURNAL OF INFECTION. 2020; 80 (4): 401-406. DOI:https://doi.org/10.1016/j.jinf.2020.02.018Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281‐286. DOI:10.1007/s12098-020-03263-6Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062. DOI:https://doi.org/10.1016/S0140-6736(20)30566-3Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.DOI: 10.1056/NEJMoa2002032Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults. Pediatric Pulmonology. 2020;55(5):1169-1174. DOI: 10.1002 / ppul.24718Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. 2020;7(1). DOI: 10.1186 / s40779-020-00240-0Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology. 2004;203(2):631-637. DOI: 10.1002/path.1570Aburizaiza A, Mattes F, Azhar E, Hassan A, Memish Z, Muth D et al. Investigation of Anti-Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012. Journal of Infectious Diseases. 2013;209(2):243-246. DOI: 10.1093/infdis/jit589Yu F, Du L, Ojcius D, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes and Infection. 2020;22(2):74-79. DOI: 10.1016/j.micinf.2020.01.003Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271. DOI:10.1038/s41422- 020-0282-0Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824–1836. DOI:10.1001/jama.2020.6019.Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. DOI:10.1016/j. ijantimicag.2020.105949Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). DOI:10.3785/j.issn.1008-9292.2020.03.03Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-214. DOI:10.1073/pnas.1617020114Khamitov RA, Loginova SIa, Shchukina VN,Borisevich SV, Maksimov VA, Shuster AM. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian]. Vopr Virusol. 2008;53(4):9-13. PMID: 18756809Wang Z, Yang B, Li Q,Wen L, Zhang R. Clinical Features of 69 cases with coronavirus disease 2019 inWuhan, China. Clin Infect Dis. DOI:10.1093/cid/ciaa272Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. DOI:10.1038/s41467-019-13940-6Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388(10043):498-503. DOI:10.1016/S0140-6736(16)30386-5Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. Published 2020 Apr 8. DOI:10.1136/bmj.m1432Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60(5): 1648-1661. DOI:10.1021/acs.jmedchem.6b01594Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615. DOI:10.1016/j.tmaid.2020.101615World Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. Published October 2018. Accessed March 20, 2020. https://www.who.int/ebola/drc-2018/summaries-of-evidenceexperimental-therapeutics.pdfHolshue ML, DeBolt C, Lindquist S, et al; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. DOI:10.1056/NEJMoa2001191Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. DOI:10.1371/journal.pmed.0030343Morra ME, Van Thanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28 (3):e1977. DOI:10.1002/rmv.1977Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397-412. DOI:10.1080/ 17460441.2019.1581171de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011;92(pt 11):2542-2548. DOI:10.1099/ vir.0.034983-0Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150. DOI:10.1038/d41573- 020-00016-0Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016;9(3):227-230. DOI:10.1016/j.jiph.2016. 04.001Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. DOI:10.1016/j.cell.2020.02.052American Heart Association. Patients taking angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blocker (ARB) medications should continue therapy as prescribed [news release]. Accessed March 18, 2020. https://newsroom.heart.org/ news/patients-taking-ace-i-and-arbs-who-contract- covid-19-should-continue-treatment-unless- otherwise-advised-by-their-physicianEuropean Society for Cardiology. Position statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Accessed March 18, 2020. https://www.escardio.org/Councils/Council- on-Hypertension-(CHT)/News/position- statement-of-the-esc-council-on-hypertension-on- ace-inhibitors-and-angArabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4:709. DOI:10.1186/s40064-015-1490-9Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456. DOI:10.1093/cid/ciq1066. Mehra M, Desai S, Ruschitzka F, Patel A. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020 ;DOI: https://doi.org/10.1016/S0140-6736(20)31180-6.Brunton L, Hilal-Dandan R, Knollmann B. Goodman & Gilman's The pharmacological basis of therapeutics. 13th ed. Auckland;976.Wang, H., Wang, Z., Dong, Y. y col. Estimación ajustada por fase del número de casos de Enfermedad por Coronavirus 2019 en Wuhan, China. Cell Discov 6, 10 (2020). DOI:https://doi.org/10.1038/s41421-020-0148-0.Sede BarranquillaMedicinaORIGINALPDF.pdfPDF.pdfapplication/pdf967020https://bonga.unisimon.edu.co/bitstreams/57522ac1-5323-4cb5-824a-16463a8011bb/downloadcf2d00e07eea1ca2ca2ae94f464143a2MD51PDF_Resumen.pdfPDF_Resumen.pdfapplication/pdf210672https://bonga.unisimon.edu.co/bitstreams/5db4a1f4-4f0c-4217-874d-b848329c994c/download2e02d18653c971dbd183b292bc06affcMD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/ef9e3b3c-711c-4c6e-a1e0-27717d82c21c/download4460e5956bc1d1639be9ae6146a50347MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-83000https://bonga.unisimon.edu.co/bitstreams/66ab097c-d307-4843-8d56-3f543f212fdf/download2a1661e5960a7bab4fd8dda692fb677cMD54TEXTCOVID-19_Revisión_Literatura_Tratamientos_Artículo.pdf.txtCOVID-19_Revisión_Literatura_Tratamientos_Artículo.pdf.txtExtracted texttext/plain39785https://bonga.unisimon.edu.co/bitstreams/6a7e6f4d-3dfb-451c-bda4-95fdd7f4b023/download147b8aa26921e4e342fbcad1633f2f29MD55COVID-19_Revisión_Literatura_Tratamientos_Resumen.pdf.txtCOVID-19_Revisión_Literatura_Tratamientos_Resumen.pdf.txtExtracted texttext/plain10490https://bonga.unisimon.edu.co/bitstreams/8d1e0fe5-094e-4653-9835-05f3d2187bb7/download82baf24a4e2edc7c5993fc6486bc718dMD57PDF.txtPDF.txtExtracted texttext/plain40681https://bonga.unisimon.edu.co/bitstreams/f4e05a1c-8f4c-4ba1-bad2-35ca3bd3bb51/download02e638b876d4862ac7436548eda23760MD59PDF_Resumen.txtPDF_Resumen.txtExtracted texttext/plain10860https://bonga.unisimon.edu.co/bitstreams/f1792514-94d4-4a0c-b3dd-c417dddc8d7a/downloada12b79e069ffd7e6808a4f0422845969MD511PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain40681https://bonga.unisimon.edu.co/bitstreams/048a5952-09f7-49d3-9501-14b9111b8860/download02e638b876d4862ac7436548eda23760MD513PDF_Resumen.pdf.txtPDF_Resumen.pdf.txtExtracted texttext/plain10860https://bonga.unisimon.edu.co/bitstreams/3a6b1244-2857-467c-829f-5d03a6b96ea8/downloada12b79e069ffd7e6808a4f0422845969MD515THUMBNAILCOVID-19_Revisión_Literatura_Tratamientos_Artículo.pdf.jpgCOVID-19_Revisión_Literatura_Tratamientos_Artículo.pdf.jpgGenerated Thumbnailimage/jpeg19376https://bonga.unisimon.edu.co/bitstreams/dd62304e-70e0-4aba-9079-c007456f9415/download3c4cd5e38e5143ac2cd1967f60a33976MD56COVID-19_Revisión_Literatura_Tratamientos_Resumen.pdf.jpgCOVID-19_Revisión_Literatura_Tratamientos_Resumen.pdf.jpgGenerated Thumbnailimage/jpeg14438https://bonga.unisimon.edu.co/bitstreams/e38d9a50-8745-4e02-95cb-90826445db9b/download4d878871ab6bee20fb82b13935760938MD58PDF.jpgPDF.jpgGenerated Thumbnailimage/jpeg5384https://bonga.unisimon.edu.co/bitstreams/7f3bbce7-b8c5-4fd3-bfca-1781a8d16868/download19ff5bdadc5d96e0328dd6c8ff9cbacdMD510PDF_Resumen.jpgPDF_Resumen.jpgGenerated Thumbnailimage/jpeg4770https://bonga.unisimon.edu.co/bitstreams/7b056d31-e096-45ff-aaea-7b9b184726c0/download855a0958350f2d2c52cc9fd0e20e1394MD512PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5384https://bonga.unisimon.edu.co/bitstreams/1b9463ac-fa94-4608-9434-7d17bbdad913/download19ff5bdadc5d96e0328dd6c8ff9cbacdMD514PDF_Resumen.pdf.jpgPDF_Resumen.pdf.jpgGenerated Thumbnailimage/jpeg4770https://bonga.unisimon.edu.co/bitstreams/1a06d243-cacd-4001-9f20-cfc37de5fa87/download855a0958350f2d2c52cc9fd0e20e1394MD51620.500.12442/7978oai:bonga.unisimon.edu.co:20.500.12442/79782024-08-14 21:53:57.418http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalrestrictedhttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.co |